Actavis Reports Exceptional Performance in First Quarter 2015 with 59% Increase in Net Revenue to $4.2 Billion and 23% Growth in Non-GAAP EPS to $4.30

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. ACN
7. IBM
8. NKE
9. MU
10. AWK

Go back to Actavis Reports Exceptional Performance in First Quarter 2015 with 59% Increase in Net Revenue to $4.2 Billion and 23% Growth in Non-GAAP EPS to $4.30

Guggenheim Raises PT After Actavis (ACT) Has 1Q15 EPS Beat

May 11, 2015 10:57 AM EDT

Guggenheim reiterates their Buy rating on Actavis (NYSE: ACT), and raised the price target to $355.00 (from $345.00), following a 1Q15 beat. ACT reported an adjusted 1Q15 diluted EPS of $4.30. This came $0.34 higher than consensus, and $0.41 better than Guggenheim estimates.

Guggenheim analyst, Louise Chen,... More

Actavis (ACT) Tops Q1 EPS by 38c

May 11, 2015 6:32 AM EDT

Actavis (NYSE: ACT) reported Q1 EPS of $4.30, $0.38 better than the analyst estimate of $3.92. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.04 billion.

"Actavis achieved exceptional operational performance while simultaneously focusing on the completion of the Allergan acquisition and accelerating the integration of our combined company to create a Growth Pharma leader," said Brent... More